Laryngeal cancer

References

Key articles

Pelucchi C, Gallus S, Garavello W, et al. Cancer risk associated with alcohol and tobacco use: focus on upper aero-digestive tract and liver. Alcohol Res Health. 2006;29(3):193-8. Abstract

Troell RJ, Terris DJ. Detection of metastases from head and neck cancers. Laryngoscope. 1995 Mar;105(3 Pt 1):247-50. Abstract

Lefebvre JL, Ang KK; Larynx Preservation Consensus Panel. Larynx preservation clinical trial design: key issues and recommendations: a consensus panel summary. Head Neck. 2009 Apr;31(4):429-41. Abstract

Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78.Full text  Abstract

Brouwer J, Hooft L, Hoekstra OS, et al. Systematic review: accuracy of imaging tests in the diagnosis of recurrent laryngeal carcinoma after radiotherapy. Head Neck. 2008 Jul;30(7):889-97. Abstract

Reference articles

1. Agarwal V, Branstetter BF 4th, Johnson JT. Indications for PET/CT in the head and neck. Otolaryngol Clin North Am. 2008 Feb;41(1):23-49. Abstract

2. Adams GL, Maisel RH. Malignant tumors of the larynx and hypopharynx. In: Cummings otolaryngology: head and neck surgery. Cummings CW, Flint PW, Harker LA, et al, eds. 4th ed. Philadelphia, PA: Elsevier Mosby; 2005:2222-83.

3. American Cancer Society. Cancer facts & figures: 2016. 2016 [internet publication].Full text

4. American Cancer Society. Cancer facts & figures: 2008. 2008 [internet publication].Full text

5. Agrawal N, Ha PK. Management of early-stage laryngeal cancer. Otolaryngol Clin North Am. 2008 Aug;41(4):757-69. Abstract

6. Devlin JG, Langer CJ. Combined modality treatment of laryngeal squamous cell carcinoma. Expert Rev Anticancer Ther. 2007 Mar;7(3):331-50. Abstract

7. Van Cauwenberge P, Dhooge I, Ingels K. Epidemiology and etiological factors of laryngeal cancer. Acta Otorhinolaryngol Belg. 1992;46:99-102. Abstract

8. Egeli U, Ozkan L, Tunca B, et al. The relationship between genetic susceptibility to head and neck cancer with the expression of common fragile sites. Head Neck. 2000 Sep;22(6):591-8. Abstract

9. Bagnardi V, Blangiardo M, La Vecchia C, et al. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer. 2001 Nov 30;85(11):1700-5.Full text  Abstract

10. Pelucchi C, Gallus S, Garavello W, et al. Cancer risk associated with alcohol and tobacco use: focus on upper aero-digestive tract and liver. Alcohol Res Health. 2006;29(3):193-8. Abstract

11. British Association of Endocrine and Thyroid Surgeons. Head, neck and thyroid cancers 2012 - vision paper. 2010.

12. Hoffman HT, Iseli TA, Karnell LH, et al. Management of early glottic cancer. In: Cummings CW, Flint PW, Haughey BH, et al, eds. Cummings otolaryngology: head and neck surgery. 4th ed. Philadelphia, PA: Elsevier Mosby; 2005:2285-2325.

13. Altieri A, Garavello W, Bosetti C, et al. Alcohol consumption and risk of laryngeal cancer. Oral Oncol. 2005 Nov;41(10):956-65. Abstract

14. El-Serag HB, Hepworth EJ, Lee P, et al. Gastroesophageal reflux disease is a risk factor for laryngeal and pharyngeal cancer. Am J Gastroenterol. 2001 Jul;96(7):2013-8. Abstract

15. Galli J, Cammarota G, Calo L, et al. The role of acid and alkaline reflux in laryngeal squamous cell carcinoma. Laryngoscope. 2002 Oct;112(10):1861-5. Abstract

16. van der Laan BF, Baris G, Gregor RT, et al. Radiation-induced tumours of the head and neck. J Laryngol Otol. 1995 Apr;109(4):346-9. Abstract

17. Yu KK, Zanation AM, Moss JR, et al. Familial head and neck cancer: molecular analysis of a new clinical entity. Laryngoscope. 2002 Sep;112(9):1587-93. Abstract

18. Ha PK, Califano JA 3rd. The molecular biology of laryngeal cancer. Otolaryngol Clin North Am. 2002 Oct;35(5):993-1012. Abstract

19. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog. 1993;7:139-146. Abstract

20. Rees L, Birchall M, Bailey M, et al. A systematic review of case-control studies of human papillomavirus infection in laryngeal squamous cell carcinoma. Clin Otolaryngol Allied Sci. 2004 Aug;29(4):301-6. Abstract

21. International Agency for Research on Cancer. Tobacco smoke and involuntary smoking: summary of data reported and evaluation. Lyon, France: IARC; 2002.Full text

22. Geisler SA, Olshan AF. GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review. Am J Epidemiol. 2001 Jul 15;154(2):95-105.Full text  Abstract

23. Wight R, Paleri V, Arullendran P. Current theories for the development of nonsmoking and nondrinking laryngeal carcinoma. Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):73-7. Abstract

24. Frumkin H. Agent Orange and cancer: an overview for clinicians. CA Cancer J Clin. 2003 Jul-Aug;53(4):245-55.Full text  Abstract

25. Lindeberg H, Elbrond O. Malignant tumours in patients with a history of multiple laryngeal papillomas: the significance of irradiation. Clin Otolaryngol Allied Sci. 1991 Apr;16(2):149-51. Abstract

26. Qadeer MA, Lopez R, Wood BG, et al. Does acid suppressive therapy reduce the risk of laryngeal cancer recurrence? Laryngoscope. 2005;115:1877-1881. Abstract

27. Seoane JT. Impact of delay in diagnosis on survival to head and neck carcinomas: a systematic review with meta-analysis. Clin Otolaryngol. 2012 Apr;37(2):99-106. Abstract

28. Troell RJ, Terris DJ. Detection of metastases from head and neck cancers. Laryngoscope. 1995 Mar;105(3 Pt 1):247-50. Abstract

29. Cancer Care Ontario. PET imaging in head and neck cancer. February 2012 [internet publication].Full text

30. Kraft M, Betz CS, Leunig A, et al. Value of fluorescence endoscopy for the early diagnosis of laryngeal cancer and its precursor lesions. Head & Neck. 2011 Jul;33(7):941-8. Abstract

31. Tesic-Vidovic L. Laryngeal tuberculosis: a report of three cases. Internet J Otorhinolaryngol. 2006;4.

32. Dipika A, Balakrishnan C, Nene A, et al. Upper airways involvement in Wegener's granulomatosis: a case report and review. J Indian Rheumatol Assoc. 2004;12:127-29.Full text

33. Amin MB, Edge S, Green F, et al. AJCC cancer staging manual. 8th ed. (2017). Cham, Switzerland: Springer International; 2017.

34. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancers [internet publication].Full text

35. Silver CE, Beitler JJ, Shaha AR, et al. Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol. 2009 Sep;266(9):1333-52. Abstract

36. Thomas L, Drinnan M, Natesh B, et al. Open conservation partial laryngectomy for laryngeal cancer: a systematic review of English language literature. Cancer Treat Rev. 2012 May;38(3):203-11. Abstract

37. Feng YW. Comparison of preoperative radiation and surgery with surgery alone for laryngeal carcinoma. Cancer Treat Rev. 2010;17:1949-52.

38. Forastiere AA, Ismaila N, Lewin JS, et al. Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018 Apr 10;36(11):1143-69.Full text  Abstract

39. Bradley PJ, Mackenzie K, Wight R, et al. Consensus statement on management in the UK: transoral laser assisted microsurgical resection of early glottic cancer. Clin Otolaryngol. 2009 Aug;34(4):367-73. Abstract

40. Higgins KM, Shah MD, Ogaick MJ, et al. Treatment of early-stage glottic cancer: meta-analysis comparison of laser excision versus radiotherapy. J Otolaryngol Head Neck Surg. 2009 Dec;38(6):603-12. Abstract

41. Warner L, Chudasama J, Kelly CG, et al. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. Cochrane Database Syst Rev. 2014 Dec 12;(12):CD002027.Full text  Abstract

42. Spielmann PM, Majumdar S, Morton RP, et al. Quality of life and functional outcomes in the management of early glottic carcinoma: a systematic review of studies comparing radiotherapy and transoral laser microsurgery. Clin Otolaryngol. 2010 Oct;35(5):373-82. Abstract

43. Lefebvre JL, Ang KK; Larynx Preservation Consensus Panel. Larynx preservation clinical trial design: key issues and recommendations: a consensus panel summary. Head Neck. 2009 Apr;31(4):429-41. Abstract

44. Tandon S, Munir N, Roland NJ, et al. A systematic review and number needed to treat analysis to guide the management of the neck in patients with squamous cell carcinoma of the head and neck. Auris Nasus Larynx. 2011 Dec;38(6):702-9. Abstract

45. Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1270-6.Full text  Abstract

46. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991 Jun 13;324(24):1685-90. Abstract

47. Ghadjar PS, Zimmermann FB. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94). Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):524-31. Abstract

48. Bourhis JS, Martin LA, ly-Schveitzer NS, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncology. 2012 Feb;13(2):145-53. Abstract

49. Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014 Sep 20;32(27):2940-50.Full text  Abstract

50. Nguyen-Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014 Dec 1;32(34):3858-66.Full text  Abstract

51. Wee JT, Anderson BO, Corry J, et al. Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009 Nov;10(11):1086-92. Abstract

52. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar 1;31(7):845-52.Full text  Abstract

53. Hristov B, Bajaj GK. Radiotherapeutic management of laryngeal carcinoma. Otolaryngol Clin North Am. 2008 Aug;41(4):715-40. Abstract

54. Paleri V, Thomas L, Basavaiah N, et al. Oncologic outcomes of open conservation laryngectomy for radiorecurrent laryngeal carcinoma: a systematic review and meta-analysis of English-language literature. Cancer. 2011 Jun 15;117(12):2668-76. Abstract

55. Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):676-81. Abstract

56. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78.Full text  Abstract

57. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: palliative care [internet publication].Full text

58. Brouwer J, Hooft L, Hoekstra OS, et al. Systematic review: accuracy of imaging tests in the diagnosis of recurrent laryngeal carcinoma after radiotherapy. Head Neck. 2008 Jul;30(7):889-97. Abstract

59. American College of Radiology. ACR Appropriateness Criteria: retreatment of recurrent head and neck cancer after prior definitive radiation. 2014 [internet publication].Full text

60. Zhang X, Zhang H, Tighiouart M, et al. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer. 2008 Sep 1;123(5):1005-14. Abstract

61. Zhang X, Chen ZG, Khuri FR, et al. Induction of cell cycle arrest and apoptosis by a combined treatment with 13-cis-retinoic acid, interferon-alpha2a, and alpha-tocopherol in squamous cell carcinoma of the head and neck. Head Neck. 2007 Apr;29(4):351-61. Abstract

62. ClinicalTrials.gov. Chemotherapy with or without bevacizumab in treating patients with recurrent or metastatic head and neck cancer. January 2016 [internet publication].Full text

63. Argiris A, Li S, Savvides P, et al. Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2019 Dec 1;37(34):3266-74.Full text  Abstract

64. Biel MA. Photodynamic therapy and the treatment of neoplastic diseases of the larynx. Laryngoscope. 1994 Apr;104(4):399-403. Abstract

65. Biel MA. Photodynamic therapy treatment of early oral and laryngeal cancers. Photochem Photobiol. 2007 Sep-Oct;83(5):1063-8. Abstract

66. Cohen EE, LaMonte SJ, Erb NL, et al. American Cancer Society head and neck cancer survivorship care guideline. CA Cancer J Clin. 2016 May;66(3):203-39.Full text  Abstract

67. National Institute for Health and Care Excellence. Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck. June 2017 [internet publication].Full text

68. Hoffman HT, Porter KP, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngscope. 2006;116:1-13. Abstract

69. Cosetti M, Yu GP, Schantz SP. Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg. 2008 Apr;134(4):370-9.Full text  Abstract

70. Cancer Research UK. Laryngeal cancer: survival. January 2020 [internet publication].Full text

71. Meyer FF. Predictors of severe acute and late toxicities in patients with localized head-and-neck cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1454-62. Abstract

72. Jacobi I, van der Molen L, Huiskens H, et al. Voice and speech outcomes of chemoradiation for advanced head and neck cancer: a systematic review. Eur Arch Otorhinolaryngol. 2010 Oct;267(10):1495-505.Full text  Abstract

73. Seixas-Silva JA Jr, Richards T, Khuri FR, et al. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. Arch Otolaryngol Head Neck Surg. 2005;131:304-307.Full text  Abstract

74. Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 1976;35:1332-1338. Abstract

75. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006;98:441-450.Full text  Abstract

76. Zhang X, Chen ZG, Choe MS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res. 2005 Sep 1;11(17):6261-9.Full text  Abstract

Use of this content is subject to our disclaimer